Tolterodine

Tolterodine

SCHEMBL4840247

Cc1ccc(O)c(C(CCN(C(C)C)C(C)C)c2ccccc2)c1.Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM2CHRM3

The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 9/20 0.97
CHRM2 known ✓ P08172 3/20 0.97
CHRM1 P11229 3/20 0.97
CHRM5 P08912 2/20 0.97
HRH1 P35367 2/20 0.97
MAPT P10636 2/20 0.97
LMNA P02545 1/20 0.97
ESR1 P03372 1/20 0.97
CHRM4 P08173 1/20 0.97
KCNE1 P15382 1/20 0.97
PTGS1 P23219 1/20 0.97
HRH2 P25021 1/20 0.97
HTR2A P28223 1/20 0.97
SLC6A4 P31645 1/20 0.97
ADRA1A P35348 1/20 0.97
OPRK1 P41145 1/20 0.97
KCNQ1 P51787 1/20 0.97
KCNH2 Q12809 1/20 0.97
CACNA1C Q13936 1/20 0.97
SCN5A Q14524 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tolterodine SCHEMBL4622977 1.00 CHRM3 (0.97) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL617185 1.00 CHRM3 (0.97) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL1262757 0.99 CHRM3 (0.95) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL29635996 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL29379290 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL580446 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL3064 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL36882 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL820421 0.99 CHRM3 (1.00) CHRM3CHRM2CHRM1CHRM5HRH1
Tolterodine SCHEMBL1260827 0.97 CHRM3 (0.97) CHRM3CHRM2CHRM1CHRM5HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7355077-B2 Process for preparing tolterodine DR. REDDY'S LABORATORIES LIMITED (IN) 2008-04-08 US claimed
US-20060094904-A1 Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol DR. REDDY'S LABORATORIES LIMITED (IN) 2006-05-04 US claimed
US-20080146844-A1 PROCESS FOR PREPARING TOLTERODINE DR. REDDY'S LABORATORIES LIMITED (IN) 2008-06-19 US disclosed
US-7355077-B2 Process for preparing tolterodine DR. REDDY'S LABORATORIES LIMITED (IN) 2008-04-08 US disclosed
US-20060094904-A1 Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol DR. REDDY'S LABORATORIES LIMITED (IN) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146844-A1 PROCESS FOR PREPARING TOLTERODINE ADRA2B, ADRB3, ADRB1 CHRM3 110/4885CHRM2 287/4885CHRM1 796/4885
US-20060094904-A1 Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol ADRB3, UGT1A3, COMT CHRM3 40/4885CHRM2 292/4885CHRM1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.